30 Stocks Moving In Monday's Mid-Day Session

Gainers

  • Yield10 Bioscience Inc YTEN shares gained 280 percent to $7.41 after the company reported granting of research license to Monsanto for evaluation of 2 novel yield traits in soybean.
  • ARGENX SE/S ADR ARGX shares jumped 55 percent to $47.19 after the company reported positive topline results from Phase 2 proof-of-concept trial of ARGX-113 in generalized myasthenia gravis.
  • Net Element Inc NETE shares climbed 52.1 percent to $6.13.
  • Shineco Inc TYHT shares rose 23.3 percent to $3.23 after the company disclosed a Share Exchange and Acquisition deal with Western Xinjiang Tiansheng Agricultural Development Co.
  • Riot Blockchain Inc RIOT shares jumped 19.6 percent to $18.98 after gaining 8.63 percent on Friday.
  • bluebird bio Inc BLUE shares gained 18.9 percent to $203.49 after the company announced updated clinical results from ongoing Phase 1 multicenter study of LentiGlobin gene therapy in severe sickle cell disease at the ASH2017.
  • Famous Dave's of America, Inc. PLAY shares rose 18.9 percent to $6.30.
  • Overstock.com Inc OSTK surged 17.7 percent to $53.05 following 13G filing from Morgan Stanley late Friday showing increased stake from 130,000 shares to 2.87 million shares.
  • Blueprint Medicines Corp BPMC surged 17 percent to $84.07 after the company announced new data from ongoing Phase 1 clinical trial of Avapritinib.
  • Seven Stars Cloud Group Inc SSC jumped 14.7 percent to $2.81.
  • SunPower Corporation SPWR climbed 14.5 percent to $9.55. Baird upgraded SunPower from Neutral to Outperform.
  • Clearside BioMedical, Inc. CLSD gained 13.6 percent to $6.6933.
  • Intersect ENT Inc XENT shares rose 13.1 percent to $32.35 as the company reported the FDA approval of SINUVA Sinus Implant as a treatment option for recurrent nasal polyps.
  • CHF Solutions Inc CHFS shares gained 12.8 percent to $3.87 after climbing 11.00 percent on Friday.
  • U.S. Global Investors, Inc. GROW shares rose 12.2 percent to $4.43.
  • Helios and Matheson Analytics Inc HMNY climbed 10.4 percent to $9.33 following news of a new marketing and performance-based sales deal with a movie distributor.
  • Sunesis Pharmaceuticals, Inc. SNSS gained 8.5 percent to $2.69. Wells Fargo upgraded Sunesis Pharmaceuticals from Market Perform to Outperform.
  • Marathon Patent Group Inc MARA gained 8.2 percent to $4.77 after declining 3.71 percent on Friday.
  • Catalyst Biosciences Inc CBIO climbed 7.7 percent to $8.12 as the company announced promising interim Phase 1/2 CB 2679D/ISU304 results at the ASH2017.
  • Trade Desk Inc TTD rose 7.5 percent to $48.64. SunTrust Robinson Humphrey upgraded Trade Desk from Hold to Buy.


Losers

  • Spark Therapeutics Inc ONCE shares dipped 42.1 percent to $42.50 on volatile factor VIII activity data in hemophilia A gene therapy.
  • Syros Pharmaceuticals Inc SYRS tumbled 37.3 percent to $7.76 following presentation at the ASH 2017 on Phase 2 trial of SY-1425 in genomically defined AML and MDS patients.
  • Athenex Inc ATNX shares dropped 16.3 percent to $13.37.
  • Juno Therapeutics Inc JUNO dipped 12.2 percent to $51.49. Juno Therapeutics and Celgene released additional data from the TRANSCEND trial of JCAR017 in patients with relapsed or refractory aggressive B-cell non-hodgkin lymphoma.
  • Anavex Life Sciences Corp AVXL shares declined 11.7 percent to $3.26. Anavex Life Sciences reported FY17 loss of $0.33 per share, versus a year-ago loss of $0.42 per share.
  • Trillium Therapeutics Inc TRIL shares fell 9.8 percent to $10.15
  • Verastem Inc VSTM shares declined 8.5 percent to $3.96 after the company announced clinical data from the pivotal Phase 3 DUO study.
  • Global Blood Therapeutics Inc GBT dropped 8.5 percent to $41.88 after the company released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition.
  • Intevac, Inc. IVAC shares dropped 8.1 percent to $6.30 after gaining 0.74 percent on Friday.
  • Seattle Genetics, Inc. SGEN shares fell 7 percent to $55.11. Seattle Genetics highlighted five-year survival results from Phase 1 trial of ADCETRIS in frontline mature T-cell lymphoma at the ASH 2017.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMovers & ShakersIntraday UpdateMarketsMoversMid-Day LosersMid-Day MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!